-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Atea Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q2 2024.
- Atea Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$46.9M, a 33.2% decline year-over-year.
- Atea Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$204M, a 53.5% decline year-over-year.
- Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$164M, a 25.7% decline from 2022.
- Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$131M, a 194% decline from 2021.
- Atea Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was $138M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)